Scienture announces shipment of launch quantities of Arbli Oral Suspension

Scienture (SCNX) announce the shipment of launch quantities of Arbli Oral Suspension, 10 mg/mL to its 3PL/Distribution Center for the intended commercial launch of the product. This shipment marks a major milestone accomplishment for Scienture, which has agreements in place for the distribution of the product through wholesalers and has received its first order for shipment in August 2025. “Shipping launch quantities of Arbli to our 3PL/Distribution Center and receiving the first order of the product mark critical milestones in our journey to bring Arbli to patients who need it the most.” said Narasimhan Mani, President and co-CEO, “We’re proud of the cross-functional effort that made this possible, from development through to manufacturing and logistics.”